Hollywood, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its subsidiary Cannabis Therapeutics Inc. are proud to announce that Dr. Moutih Rafei, PhD, has joined the company’s Advisory Board and that three out of the five distinguished scientists and doctors who were recently nominated to the companies’ Advisory Board will meet on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec, (http://www.cqib.org).
There will be a press availability and photo op.
Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei will meet at the biotech business incubator to review and discuss ETST’s ongoing R&D projects and chart the direction of the company’s research and development initiative for near future. Missing from the gathering will be Dr. Laurent Azoulay and Dr. Calvin Higgins, M.D. who cannot leave their current work at this time. Also in attendance will be Dr. Michel Aubé, PhD, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc.
At this meeting, the company will also formally launch its R&D partnership with Smart Medicine, Inc. who will provide laboratory and technical services to ETST in their facility at CQIB.
ESTS R&D is focused on the development and manufacturing of nutraceutical products, generic drugs, and cannabiniod-based medicine. The company’s goal is to market its new generic drug formulations and to find new applications for those generic drugs. The development of new improved formulations of existing generic drugs will aid in the discovery of treatment for diseases that are not currently treated with those generic drugs.
It is commonly known in the pharmacology community that most drugs act on biological targets that differ from those they were designed to treat. Drug repurposing is the name given to the process of finding new uses for existing drugs. Drug repurposing can be a very quick and economical way to bring a new, profitable drug to market. This is an important step for ETST. Existing drugs have been identified as potential ligands for the cannabinoid receptor 2 (CB2), in which ETST has a great deal of interest. Targeting CB2 with an existing drug can open up many new opportunities for the use of these existing generic drugs.
This important meeting will set the direction of ETST and Cannabis Therapeutics, Inc. and is of major interest to investors contemplating the coming cannabis investment boom.
The meeting will also be the first occasion for Dr. Moutih Rafei, the newest addition to the Advisory Board, to meet with other members.
Dr. Moutih Rafei has been an Assistant Professor in the Department of Pharmacology & Physiology of the Université de Montréal since 2013. He completed a PhD in Experimental Medicine at McGill University and his post-doctoral training in Immunobiology at the Université de Montréal. During his training, Dr. Rafei accumulated profound knowledge and insight in the fields of T-cell development and stem cell biology, cancer immunotherapy, and autoimmune diseases. He is also actively involved in the discovery and development of small molecules that may stimulate or inhibit the immune system for the treatment of certain catastrophic illnesses.
About Earth Science Tech, Inc. (ETST): Earth Science Tech (www.earthsciencetech.com) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.